Six clinically healthy blood donor dogs were used to evaluate the effect of desmopressin (DDAVP) on haemochromocytometric and clotting parameters,. They received subcutaneously a physiological solution (placebo) and DDAVP (1microg/kg) with a two-weeks wash-out period between treatments. Blood samples were collected immediately before the injection, after 30 minutes, then after 1, 2, 3, 4, 5 and 6 hours. Two-way repeated measure analysis of variance (ANOVA) showed no significant effect of DDAVP vs placebo, except for white blood cell (WBC) count, and in particular on neutrophils. In conclusion, DDAVP administration in healthy donor dogs does not induce modification in blood cell count and clotting parameters, except of WBC.
desmopressin; clotting time parameters; hemochromocytometric parameters; dog; blood donor
Balduini CL, Noris P, Belletti S, Spedini P, Gamba G: In vitro and in vivo effects of desmopressin on platelet function. Haematologica 84:891-896, 1999.
Cattaneo M, Tenconi PM, Alberca I, Garcia VV, Mannucci PM: Subcutaneous desmopressin (DDAVP) shorterns the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 64:358-360, 1990.
Dodds WJ: 2nd International Registry of Animal Models of Thrombosis and Hemorrhagic Diseases. National Academic Press, Washington 1981.
Giles AR, Tinlin S, Greenwood R: A canine model of hemophilic (Factor VIII:C Deficiency) bleeding. Blood 60:727-730, 1982.
Hashemi S, Palmer DS, Aye MT, Ganz PR: Platelet activating factor secreted dy DDAVP-treated monocytes mediates von Willebrand factor release from endothelial cells. J Cell Physiol 154:496-505, 1993.
Hohenhaus AE: Management of the inpatient canine blood donor. Probl Vet Med 4 (4):565-571, 1992.
Johnson GS, Kraus KH, Turrentine MA, Dean PW: DDAVP-induced increases in coagulation factor VIII and von Willebrand factor in the plasma of conscious dogs. J Vet Pharmacol Ther 9 (4):70-75, 1986.
Johnstone IB: Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with Type 1 von Willebrand's disease. Can Vet J 40:645-645, 1999.
Johnstone IB, Crane S: The effects of desmopressin on hemostatic parameters in the normal dog. Can J Vet Res 50:265-271, 1986.
Kam PC: Use of desmopressin (DDAVP) in controlling aspirin-induced coagulopathy after cardiac surgery. Heart Lung 23:333-336, 1994.
Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck LK, Kubes P: Desmopressin induces endothelial P-selectin expressin and leukocyte rolling in postcapillary venules. Blood 86:2760-2766, 1995.
Kaufmann JE, Vischer UM: Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 1:682-689, 2003.
Kavakli K, Huseyinov A, Coker I, Aydinok Y, Nisli G: Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease. Haemophilia 7:482-489, 2001.
Kohler M, Harris A: Pharmacokinetics and haematological effects of desmopressin. Europ J Clin Pharmacol 35:281-285, 1988.
Kraus KH, Turrentine MA, Jergens AE, Johnson GS: Effects of desmopressin acetate on bleeding times and plasma von Willebrand factor in Doberman pinscher dogs with von Willebrand's disease. Vet Surg 18:103-109, 1989.
Lethagen S: Desmopressin - a haemostatic drug: state of art review. Europ J Anaesthesiol 14:1-9, 1997.
Lucas RL, Lentz KD, Hale AS: Collection and preparation of blood products. Clin Tech Small Anim Pract 19 (2):55-62, 2004.
Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90:2515-2521, 1997.
Palacios S, Zuazu I, Candela MJ, Rivera J, Vincente V: Subcutaneous administration of desmopressin to plasma donor: a controlled study. Med Clin (Barc) 105 (14):525-527, 1995.
Pomper GJ, Rick ME, Epstein JS, Read EJ, Leitman SF: Management of severe VWD with cryoprecipitate collected by repeated apheresis of a single dedicated donor. Transfusion 43:1514-1521, 2003.
Randels MJ, Strauss RG, Cordle D, Koerner TA, Floss AS: Donor reactions during DDAVP-stimulated plasmapheresis. J Clin Apher 7 (2):78-80, 1992.
Sakai M, Watari T, Miura T, Maruyama H, Koie H, Yamaya Y, Takeuchi A, Hasegawa A: Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases. J Vet Med Sci 65:83-86, 2003.
Sato I, Parry BW: Effect of desmopressin on plasma factor VIII and von Willebrand factor concentrations in Greyhounds. Aust Vet J 76:809-812, 1998.
Sutor AH, Pollmann H, Arends P: Intranasale anwendung von DDAVP bei schwerer Hamophilie A und B. In Sutor AH (ed.): International Symposium on DDAVP in Bleeding Disorders. Schattauer-Verlag, Stuttgart, New York 1980, pp. 109-114.
Sutor AH: DDAVP is not a panacea for children with bleeding disorders. British J Haematol 108:217-227, 2000.
Tomasiak MM, Stelmach H, Bodzenta-Lukaszyk A, Tomasiak M: Involvment of Na+/H+ exchanger in desmopressin-induced platelet procoagulant response. Acta Biochim Pol 51:773-788, 2004.
Giudice E, Giannetto C, Gianesella M. Effect of desmopressin on immune-mediated haemorrhagic disorders due to canine monocytic ehrlichiosis: a preliminary study. J Vet Pharmacol Therap. 33: 610-614, 2010.